Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 19Unknown 9Recruiting 9Terminated 3Withdrawn 2Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Leukemia, Myeloid, Acute 58Breast Neoplasms 54Lymphoma 52Multiple Myeloma 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Leukemia 48Lymphoma, Non-Hodgkin 46Melanoma 43Lymphoma, Large B-Cell, Diffuse 41Leukemia, Lymphocytic, Chronic, B-Cell 40Myelodysplastic Syndromes 39Lymphoma, Follicular 29Burkitt Lymphoma 25Hodgkin Disease 24Neoplasm Metastasis 22Recurrence 21Neoplasms 21Lymphoma, Mantle-Cell 20Lymphoma, B-Cell, Marginal Zone 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Ovarian Neoplasms 17Carcinoma, Non-Small-Cell Lung 17Primary Myelofibrosis 14Neoplasms, Plasma Cell 14Myeloproliferative Disorders 14Lymphoma, B-Cell 14Hematologic Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Carcinoma, Renal Cell 13Triple Negative Breast Neoplasms 12

Interventions

Lenalidomide 5Rituximab 4Brentuximab Vedotin 4Vincristine 3Etoposide 3Cyclophosphamide 3romidepsin 2Vorinostat 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Doxorubicin 2Dasatinib 2tislelizumab 1selinexor 1plerixafor 1pembrolizumab 1pegfilgrastim 1parsaclisib 1obinutuzumab 1obatoclax 1monomethyl auristatin E 1liposomal doxorubicin 1ixazomib 1idelalisib 1ibrutinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1etoposide phosphate 1denileukin diftitox 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell, Peripheral × Cyclophosphamide × Clear all
NCT05883449 2025-08-20

LuminICE-203

Affimed GmbH

Phase 2 Terminated
25 enrolled 21 charts
Lymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04548700 2024-03-07

Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1 Terminated
38 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT00632827 2020-04-27

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

University of California, San Francisco

Phase 2 Terminated
21 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡